Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Maïlys De Sousa Mendes und 13 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Ltd (Certara Predictive Technologies), Sheffield S1 2BJ, U.K. Hauptthemen laut MEDLINE: Digoxin, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Lilly Laboratories porcine kidney 1 (LLC-PK1) and Madin-Darby canine kidney (MDCK) cell lines are commonly used in studying both passive and active drug transport, particularly through permeation assays, and, when transfected with human MDR1, to assess P-glycoprotein (P-gp)-mediated drug clearance. However, the substantial variability in experimental outcomes, including P-gp activity, presents a significant challenge to drug development and transporter research. In this study, P-gp protein expression levels were quantified in 8 cell lines used across different laboratories to evaluate digoxin transfer in a Transwell assay. P-gp activity was estimated using both conventional analysis methods and an in vitro modeling approach. Parameters derived from conventional methods, such as apparent permeability (Papp) and Michaelis-Menten parameters (Km,app and Jmax), exhibited notable interlaboratory variability and could increase the risk of underestimating the impact of transporters and their saturation when used in a physiologically based pharmacokinetic (PBPK) model. By contrast, modeling-based estimates of P-gp activity demonstrated a strong correlation with absolute transporter abundance in the cell lines. This expression-function relationship supports the accurate scaling of the P-gp activity across tissues based on expression levels. A PBPK model for digoxin was developed incorporating P-gp activity in key organs, scaled according to measured expression. These findings underscore the importance of quantifying transporter expression in in vitro systems and integrating this information into a modeling framework to enable reliable in vitro-to-in vivo extrapolation (IVIVE).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara UK Ltd (Certara Predictive Technologies), Sheffield S1 2BJ, U.K.
- Eli Lilly and Company Limited, Global PK/PD & Pharmacometrics, Bracknell RG12 1PU, U.K.
- Bristol Myers Squibb, Princeton, New Jersey 08648, United States.
- Johnson & Johnson, Preclinical Sciences & Translational Safety, Beerse 2340, Belgium.
- UCB, Braine l'Alleud 1420, Belgium.
- Novartis Pharma AG, Basel 4056, Switzerland.
ORCID-Profile: Maïlys De Sousa Mendes, Oliver Poetz, Helen Sophie Hammer, Csilla Temesszentandrási-Ambrus, Jacek R Wisniewski, Sibylle Neuhoff
Zitieren
APA
De Sousa Mendes, M., Pilla-Reddy, V., Shen, H., Moss, D. M., Chapy, H., Poller, B., Nakakariya, M., Poetz, O., Hammer, H. S., Tsai, A., Chen, B., Temesszentandrási-Ambrus, C., Wisniewski, J. R., & Neuhoff, S. (2026). Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01878
Vancouver
De Sousa Mendes M, Pilla-Reddy V, Shen H, Moss DM, Chapy H, Poller B, et al. Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01878
BibTeX
@article{DeSousaMendes2026,
author = {De Sousa Mendes, Maïlys and Pilla-Reddy, Venkatesh and Shen, Hong and Moss, Darren M and Chapy, Hélène and Poller, Birk and Nakakariya, Masanori and Poetz, Oliver and Hammer, Helen Sophie and Tsai, Alice and Chen, Buyun and Temesszentandrási-Ambrus, Csilla and Wisniewski, Jacek R and Neuhoff, Sibylle},
title = {Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01878}
}
EUVIMED